Experience

Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 7,035,000 shares of common stock of Forty Seven, Inc. Forty Seven’s…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $100 million initial public offering of common stock of Magenta…

Davis Polk advised the underwriters in connection with an initial public offering of 7,359,998 shares of common stock of Aptinyx Inc., at $16.00 per share (which includes the exercise in…

Davis Polk advised Kadmon Holdings, Inc. in connection with a $113.2 million offering of 32,022,728 shares of common stock, which included the full exercise of the underwriters’ option to…

Davis Polk advised the joint book-running managers in connection with the $172 million public offering of common stock of Deciphera Pharmaceuticals, Inc. The common stock is listed on…

Davis Polk advised Valeant Pharmaceuticals International, Inc. in connection with a refinancing transaction pursuant to which its indirect wholly owned subsidiary, Valeant Pharmaceuticals…

Davis Polk advised the representatives of the several underwriters in connection with Iterum Therapeutics plc’s initial public offering of 6,150,000 ordinary shares, at $13.00 per…

Davis Polk advised the representatives of the underwriters in connection with the SEC-registered offering of 24,640,000 shares of common stock of Melinta Therapeutics, Inc., including…

Davis Polk advised the joint book-running managers for a $50 million public offering of common stock by Ardelyx, Inc. The common stock is listed on the NASDAQ Global Market under the…

Davis Polk advised the joint book-running managers in connection with the $86.25 million public offering of common stock of Coherus BioSciences, Inc. Based in Redwood City, California,…